 Flexion Therapeutics NASDAQ:FLXN was upgraded by equities researchers at BidaskClub from a hold rating to a buy rating in a report issued on Friday, BidAskClub reports. A number of other analysts have also issued reports on FLXN. Northland Securities began coverage on shares of Flexion Therapeutics in a research note on Tuesday, June 2nd. They ... 